
CNTA Stock Forecast & Price Target
CNTA Analyst Ratings
Bulls say
Centessa Pharmaceuticals PLC is poised for substantial growth in its ORX750 product, as market share projections for orexin agonists in Narcolepsy Type 2 (NT2) and Idiopathic Hypersomnia (IH) have been increased to 60%, reflecting the widening therapeutic potential of its pipeline. Furthermore, the company's clinical studies suggest that management may achieve greater efficacy in treating Narcolepsy Type 1 (NT1) compared to competitors, enhancing its competitive positioning and revenue generation potential. Additionally, the evolution of other products in its pipeline, such as ORX142 and ORX489, indicates a strategic expansion into neurodegenerative and neuropsychiatric disorders, broadening Centessa’s market reach and reinforcing a positive long-term outlook.
Bears say
Centessa Pharmaceuticals exhibits fundamental concerns due to the declining efficacy of its key asset, Oveporexton, which showed a significant drop in placebo-adjusted mean wakefulness time (MWT) from 23 minutes in phase 2b trials to below 20 minutes in phase 3 trials. Additionally, uncertainties surrounding the long-term efficacy of orexin agonists for various sleep disorders, coupled with the challenges posed by substantial placebo effects and baseline variability in clinical trials, further complicate their product's therapeutic potential. These factors raise a red flag regarding the robustness of Centessa's clinical pipeline and its ability to achieve sustainable commercial viability.
This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.
CNTA Analyst Forecast & Price Prediction
Start investing in CNTA
Order type
Buy in
Order amount
Est. shares
0 shares